Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.

Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Co-founded by Sebastian Nijman and Thijn Brummelkamp in 2017, Scenic Biotech is a spinout of the Netherlands Cancer Institute and Oxford University. It was established with a focus on identifying genetic modifiers, or genes that suppress or block the disease-causing effects of a mutated gene in the body. In Vivo spoke with incoming CEO Oscar Izeboud about the company’s next steps, and the potential for genetic modifiers to address unmet needs in the rare disease space, and beyond.